The objective of this study proposal is to determine whether pharmacologic optimization of
voriconazole by means of therapeutic drug monitoring (TDM) results in improved patient
outcomes (efficacy and safety) and is more cost-effective compared to the current standard of
care.
Phase:
Phase 3
Details
Lead Sponsor:
Jan-Willem C Alffenaar JWC Alffenaar
Collaborators:
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) Erasmus Medical Center Haga Hospital Haga Hospital, Leyweg Klinikum Oldenburg gGmbH Leiden University Medical Center Meander Medical Center St. Antonius Hospital UMC Utrecht University Medical Center Nijmegen VU University Medical Center